Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Trey HarknessDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Abigail L SedlacekDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Keya ShahDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Alyssa M JuergensDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
Joel GreenbergerDepartment of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Amitava MukherjeeDepartment of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Robert J BinderDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0003-0857-3949
Funding
Training in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2M
CD91 and cancer immunosurveillanceR01CA233803 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BINDER, ROBERT J · 2020 to 2024
$1.7M
Mitigation of hematopoietic acute radiation syndrome (ARS) by inhibition of tyrosine kinase FgrU01AI186994 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, JOEL S GREENBERGER · 2025 to 2026
$1.1M
Co-stimulation of T cell responses to nascent, emerging tumorsR21CA286410 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder · 2025 to 2026
$388k
Heat shock proteins and modulation of immune responsesR21CA208833 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BINDER, ROBERT J · 2016 to 2017
CD91 serves as a receptor that causes the activation of antigen-presenting cells in response to cancer cells by binding HSPs. In this context, the HSP-CD91 axis is responsible for the rejection of emerging and nascent cancers. The role of CD91 in the cross-presentation of HSP-chaperoned peptides is well established, but its contribution to cell signaling and costimulation is less clear. We investigated CD91-mediated signaling with respect to cancer immunosurveillance by examining two key adaptor proteins, Fgr and AXL. To investigate the interactions between the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Disruption of CD91 association with AXL and Fgr abrogates HSP-mediated signaling and cancer immunosurveillance. · full record | Socratic